Last reviewed · How we verify
Ketotifen/naphazoline
Ketotifen is a mast cell stabilizer and H1-receptor antagonist, while naphazoline is a selective alpha-1 adrenergic agonist, together reducing allergic inflammation and vasoconstriction in the eye.
Ketotifen is a mast cell stabilizer and H1-receptor antagonist, while naphazoline is a selective alpha-1 adrenergic agonist, together reducing allergic inflammation and vasoconstriction in the eye. Used for Allergic conjunctivitis, Ocular itching and redness associated with allergies.
At a glance
| Generic name | Ketotifen/naphazoline |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Mast cell stabilizer / antihistamine / decongestant combination |
| Target | H1 receptor, mast cells, alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Allergy |
| Phase | Phase 3 |
Mechanism of action
Ketotifen prevents mast cell degranulation and blocks histamine H1 receptors to reduce allergic symptoms, while naphazoline acts as a decongestant by stimulating alpha-1 adrenergic receptors on blood vessels to reduce redness and swelling. This combination addresses both the inflammatory and vascular components of allergic eye disease.
Approved indications
- Allergic conjunctivitis
- Ocular itching and redness associated with allergies
Common side effects
- Ocular irritation
- Headache
- Mydriasis
- Transient stinging
Key clinical trials
- Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis. (PHASE3)
- Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |